Pete Brescia

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Gary Prescott

Université de Montréal

Brad Larson

Agilent Technologies (United States)

Kevin Lowitz

Cancer Research Center

Wendy Goodrich

BioTek (United States)

Bryan D. Marks

LabCorp (United States)

David J. W. Piper

Dalhousie University

Peter Banks

Newcastle University

Paul Held

BioTek (United States)

Cooperative Institutions

BioTek (United States)

Green Tech Labs (United States)

Université de Montréal

Clinical Research Institute

Montreal Clinical Research Institute

Agilent Technologies (United States)

Florida Agricultural and Mechanical University

Hewlett-Packard (United States)

Rochester Institute of Technology

Bellbrook Labs (United States)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Automation of Predictor™ hERG Fluorescence Polarization Assay using Precision™ Automated Pipetting System for Serial Dilution of Small Molecule Drugs for IC 50 Determinations

Wendy Goodrich Peter Banks Pete Brescia Paul Held Brad Larson

The vast majority of drugs associated with acquired QT prolongation are known to interact with hERG. Due to the awareness of the potential danger of such QT drugs, the regulatory authorities issued recommendations for the establishment of cardiac safety testing during preclinical drug development. Traditionally, lead compounds in late stage preclinical studies were tested for hERG binding using electrophysiology. These are laborious methods, requiring significant skill in the end-user to perform a successful assay. Furthermore, many researchers wish to test lead compounds for safety earlier in the process of drug development. This requires a higher throughput type of assay. Here we describe methods for the automation of hERG screening using Invitrogen’s fluorescence polarization based Predictor™ assay using the Precision™ Automated Pipetting System for the serial dilution of known inhibitors of hERG to generate IC50 data. FP-based IC50 data will be compared to electrophysiology and radiometric data.

hERG

Safety pharmacology

Drug Development

Source

Cite

Citations (0)